Skip to content
Business websites
Business websites
Johnson & Johnson
J&J MedTech
Johnson & Johnson
J&J MedTech
Location
Language
English
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Sweden
Svensk
Switzerland
Deutsch
Français
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America & the Carribbean
Español
English
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Specialty ophthalmology
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Our culture
Career stories
Explore jobs
Career development
Newsroom
Press releases
Media contacts
Blogs
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Specialty ophthalmology
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Our culture
Career stories
Explore jobs
Career development
Newsroom
Press releases
Media contacts
Blogs
Menu
Search Query
Submit Search
Show Search
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Submit
208 Results
208 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Neuroscience
Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session
October 3, 2024
United States
Learn more
Oncology
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
October 2, 2024
Portugal
Learn more
Oncology
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
September 30, 2024
United States
Learn more
Oncology
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
September 27, 2024
Brazil
Learn more
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
September 27, 2024
Brazil
Learn more
Oncology
TALVEY
®
(talquetamab-tgvs) and DARZALEX
FASPRO
®
(daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
September 27, 2024
United States
Learn more
Oncology
Novel combination of TALVEY
®
(talquetamab-tgvs) and TECVAYLI
®
(teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
September 27, 2024
Learn more
Oncology
DARZALEX
®
(daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
September 20, 2024
Belgium
Learn more
Oncology
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
September 19, 2024
United States
Learn more
Oncology
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence
September 16, 2024
Spain
Learn more
1 of 21
Next
Featured stories
Connecting the best of Health&Care
Learn more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Learn more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Learn more
What is a gene mutation?
Learn more